logo
  

Satsuma Pharma Reports Positive Results Early-stage Study Of STS101

Shares of Satsuma Pharmaceuticals, Inc. (STSA) are gaining over 13% in extended trading session on Wednesday after the clinical-stage biopharmaceutical company announced positive results from early-stage study of STS101.

Satsuma Pharmaceuticals reported positive pharmacokinetic, tolerability and safety results from a phase 1 trial of STS101. The study data showed that all three dose strengths administered with Satsuma's improved second-generation nasal delivery device were well-tolerated and achieved the target pharmacokinetic profile.

Satsuma said it is initiating its SUMMIT Phase 3 efficacy trial with the 5.2 mg dosage strength of STS101.

"The totality of data generated in our STS101 development program, including these new Phase 1 data and improved delivered dose results, strongly support evaluating the 5.2 mg dosage strength of STS101 in the upcoming SUMMIT Phase 3 efficacy trial," stated John Kollins, Satsuma's President and Chief Executive Officer.

STSA closed Wednesday's trading at $4.95, up $0.03 or 0.61%, on the Nasdaq. The stock further gained $0.66 or 13.33%, in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hormel Foods Corp. (HRL) said, in the fourth quarter, the company delivered earnings per share comparable with record results last year, which included an additional week of sales. Pretax earnings were $357 million, up 1% from a year ago. Organic net sales were up 2%, excluding the impact of an additional... Over the Thanksgiving holiday weekend, from Thanksgiving Day to Cyber Monday, around 196.7 million Americans shopped in stores and online, higher than the previous year, according to the National Retail Federation or NRF. Black Friday continued to be the most favored day for in-store as well as online shopping during the five-day holiday period. Lenoir, North Carolina -based Exela Pharma Sciences, LLC has expanded its recall of Sodium Bicarbonate Injection due to vial breakage to include more lots, the U.S. Food and Drug Administration said. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton.
RELATED NEWS
Follow RTT